Glecaprevir-Pibrentasvir (Maviret)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Glecaprevir-pibrentasvir (Maviret) tablet (100 mg glecaprevir / 40 mg pibrentasvir) or granules (50 mg glecaprevir / 20 mg pibrentasvir) per sachet taken orally. Indication: For the treatment of acute and chronic HCV infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.